You've asked a thought-provoking hypothetical question about whether transplanting or genetically engineering tissues, perhaps even derived from tumors or forming new organ-like structures, could secrete insulin to treat diabetes mellitus. This query touches upon cutting-edge areas of biomedical research aimed at restoring the body's natural insulin production, potentially revolutionizing diabetes management. As of today, Saturday, 2025-04-19, while the direct transplantation of malignant tumors is not a viable therapeutic strategy, related concepts involving cell transplantation and genetic engineering are actively being pursued.

Key Insights

• Islet Transplantation: A current experimental therapy involves transplanting insulin-producing islet cells from donor pancreases to restore natural insulin secretion, though challenges like immune rejection persist.
• Genetic Engineering Frontiers: Researchers are actively engineering various cell types (including stem cells and sometimes utilizing knowledge gained from tumor cell lines in lab settings) and creating lab-grown 'organoids' to produce insulin in a controlled manner.
• Tumor Transplantation Not Viable: Directly transplanting cancerous tumors to produce insulin is not pursued due to significant safety risks (uncontrolled growth, malignancy). However, research sometimes involves genetically modifying cell lines derived from tumors (like insulinomas) under controlled laboratory conditions.

Current Transplant Approaches: Restoring Natural Function

Existing experimental therapies focus on replacing or supplementing the function of the pancreas's insulin-producing cells.

Pancreatic Islet Transplantation

What it entails

One of the most established experimental methods is pancreatic islet transplantation. Islets are tiny clusters of cells within the pancreas containing beta cells, which naturally produce and secrete insulin in response to blood sugar levels. In this procedure, islets are isolated from a deceased donor's pancreas and infused into the recipient, typically into the portal vein of the liver. Once engrafted, these cells can sense glucose levels and release insulin accordingly.

Goals and Outcomes

The primary goal is to restore the body's own regulated insulin secretion, leading to better blood glucose control, reduced risk of severe hypoglycemia (low blood sugar), and potentially eliminating the need for daily insulin injections. Studies have shown that transplanted islets can function for years, significantly improving quality of life and potentially halting the progression of diabetes-related complications.

Current diabetes management often involves insulin delivery via infusion pumps or injections, which transplantation aims to replace.

Hurdles Remain

Despite its promise, islet transplantation faces significant challenges. Firstly, the supply of donor pancreases is limited. Secondly, the recipient's immune system often recognizes the transplanted cells as foreign and attacks them (rejection). To prevent this, patients require lifelong immunosuppressive drugs, which carry their own risks, including increased susceptibility to infections and certain cancers. Lastly, the transplanted islets may gradually lose function over time.

Whole Pancreas Transplantation

A More Invasive Option

Transplanting the entire pancreas is another, albeit less common, option. This procedure can fully restore normal insulin production. However, it involves major surgery and carries significant risks. It is typically reserved for individuals with type 1 diabetes who are also undergoing a kidney transplant or those with severe, life-threatening complications from diabetes that cannot be managed otherwise. Like islet transplantation, it necessitates lifelong immunosuppression.

The Frontier of Genetic Engineering: Building Insulin Factories

Recognizing the limitations of transplantation, researchers are exploring genetic engineering to create customized, sustainable sources of insulin-producing cells.

Engineering Cells for Insulin Production

Modifying Cells to Make Insulin

Scientists are working on genetically modifying various types of cells—such as stem cells or even other mature cell types like liver cells—to produce and secrete insulin. The goal is to insert the human insulin gene along with regulatory elements that allow the cells to release insulin appropriately in response to changing glucose levels.

Ensuring Glucose Responsiveness

A critical aspect is ensuring these engineered cells don't just produce insulin, but release it at the right time and in the right amounts. Uncontrolled insulin release could lead to dangerous hypoglycemia. Therefore, research focuses on creating cells that mimic the sophisticated glucose-sensing and insulin-secreting mechanisms of natural beta cells.

Novel Control Mechanisms

Beyond mimicking natural processes, innovative approaches are being explored. For instance, research has demonstrated engineered human cells that produce insulin when stimulated by a small electric current, potentially allowing for external control. Another advanced area involves designing "synthetic gene circuits" within cells. These circuits act like biological computers, sensing metabolic signals (like glucose or fatty acids) and triggering the production of therapeutic proteins, such as insulin, on demand.

The Role of Tumor-Derived Cells (Research Context)

Your question specifically mentioned tumors. While transplanting a *cancerous* tumor is not a therapeutic strategy due to obvious dangers, some early *research* has utilized cell lines derived from tumors, particularly insulinomas (pancreatic tumors that naturally overproduce insulin). Scientists have genetically engineered these lab-grown cell lines (like K cells mentioned in some studies) to control their insulin production, linking it to glucose levels. This allows researchers to study insulin secretion mechanisms in a controlled environment. It's crucial to differentiate this laboratory use from any notion of transplanting malignant tissue into patients. Historical animal studies also involved transplantable insulin-producing tumors (e.g., in irradiated rats) purely for research purposes.

Creating Insulin-Secreting Organoids

Lab-Grown Mini-Organs

A particularly exciting development is the creation of pancreatic organoids, sometimes called human islet-like organoids (HILOs). These are three-dimensional structures grown in the lab from stem cells (like pluripotent stem cells) or other progenitor cells. They are coaxed to differentiate into various pancreatic cell types, including insulin-producing beta cells, forming structures that resemble natural islets.

Potential Advantages

Organoids offer several potential advantages. They could provide a virtually unlimited supply of insulin-producing tissue, overcoming the donor shortage. Furthermore, because they can be generated from a patient's own cells (after reprogramming them into stem cells), they might be less likely to be rejected by the immune system, potentially reducing or eliminating the need for immunosuppressive drugs. Research is also exploring ways to engineer these organoids to be "invisible" to the immune system.

Enhancing Functionality

To improve the survival and function of organoids after transplantation, scientists are incorporating other cell types, such as endothelial cells (which form blood vessels), into the structure. This helps the organoids integrate better with the host's blood supply, ensuring they receive the nutrients and oxygen needed to function effectively. Studies in animal models have shown promising results, with engineered organoids successfully reversing diabetes.

Research into engineered tissues and organoids represents a move towards more sophisticated, potentially curative therapies.

Visualizing the Landscape: Comparing Approaches

To better understand how these experimental approaches stack up against current treatments and each other, we can visualize some key characteristics. The following chart provides a simplified comparison based on current understanding and future goals.

Comparative Aspects of Treatment Approaches

This radar chart compares conventional insulin injections, current islet transplantation, and the theoretical potential of future engineered cells/organoids across several factors. Higher scores generally indicate more favorable characteristics (e.g., higher Efficacy, lower Invasiveness, lower Immunosuppression need).

Key Concepts in Engineered Insulin Production

The field involves a complex interplay of biological and technological concepts. This mindmap outlines the major themes:

Addressing Safety and Feasibility

While the potential is exciting, significant hurdles must be overcome before these experimental approaches become standard treatments.

Why Not Transplant Tumors Directly?

As mentioned earlier, directly transplanting a naturally occurring insulin-secreting tumor (insulinoma) or any malignant tumor is not a viable therapeutic strategy. The primary reasons include:

• Malignancy Risk: Cancerous cells grow uncontrollably and can spread (metastasize) throughout the body, which is inherently dangerous.
• Uncontrolled Secretion: Insulinomas typically secrete insulin erratically and excessively, leading to severe and unpredictable hypoglycemia (dangerously low blood sugar), which can be life-threatening.
• Pathological Nature: These tumors are disease states that require treatment (usually surgical removal), not conditions to be harnessed for therapy.

The focus is therefore on highly controlled, engineered cells or tissues where insulin production can be precisely regulated and the risk of uncontrolled growth is minimized through careful design and testing.

Hurdles and Future Directions

The path to clinical application for engineered insulin-producing tissues involves overcoming several major obstacles:

• Immune System: Preventing rejection without long-term, broad immunosuppression remains a primary challenge.
• Durability: Ensuring the transplanted cells or tissues survive and function reliably for many years.
• Safety: Rigorously demonstrating that engineered cells will not form tumors or cause other adverse effects.
• Regulation: Achieving precise, physiological control of insulin secretion in response to blood glucose fluctuations.
• Scalability: Developing methods to produce these cells or organoids in the large quantities needed for widespread clinical use.

The future likely lies in combining advances in stem cell biology, gene editing (like CRISPR), tissue engineering, biomaterials (for encapsulation or support), and immunology to create safe, effective, and durable solutions for restoring insulin production in people with diabetes.

Related Technologies and Insights

While researchers work on biological cures, technology also offers ways to manage diabetes by automating insulin delivery.

The "Artificial Pancreas"

Often referred to as automated insulin delivery (AID) systems or closed-loop systems, the "artificial pancreas" is not a biological organ but a technological solution. It typically consists of three components: a continuous glucose monitor (CGM) that tracks blood sugar levels, an insulin pump that delivers insulin, and a control algorithm (often running on a smartphone or integrated into the pump) that automatically adjusts insulin delivery based on the CGM readings. These systems significantly improve glucose control and reduce the burden of diabetes management for many users, mimicking some aspects of natural pancreatic function.

Artificial pancreas systems combine CGM and insulin pumps for automated delivery.

Video Insight: Islet Cell Transplantation Explained

To provide more context on one of the key experimental transplantation methods discussed, the following video offers an overview of islet cell transplantation for type 1 diabetes. It helps illustrate the procedure and its goals as researchers work towards improving diabetes treatment beyond conventional methods.

This video discusses islet cell transplantation, a procedure where insulin-producing cells from a donor pancreas are infused into a patient, usually targeting individuals with difficult-to-control type 1 diabetes. It highlights the potential to restore natural insulin production and improve glucose stability, touching upon the experimental nature and ongoing research in this field, which serves as a stepping stone towards more advanced cell-based therapies like engineered organoids.

Understanding the Basics: Key Terms

Navigating this topic involves some specific terminology. This table provides brief definitions for key concepts:

Frequently Asked Questions (FAQs)

References

• A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion - PMC
• Glucose-dependent insulin release from genetically engineered K cells - PubMed
• Insulin-Producing Organoids: Hope for Treating Type 1 Diabetes - NIH Director's Blog
• Recent advances in designing implantable insulin-secreting heterocellular islet organoids to increase the efficacy of islet transplantation therapy - PubMed
• Pancreas and Islet Transplantation in Type 1 Diabetes Mellitus: Strengths and Weaknesses - PMC
• ‘Gentle’ islet cell transplant cures mice of diabetes without immunosuppression - Stanford Medicine News
• Generation of insulin-secreting organoids: A step toward transplantation therapy for diabetes mellitus - PMC

Recommended

• Explore the latest advancements in islet cell encapsulation technology to avoid immunosuppression.
• Discover how stem cells are being used to generate functional beta cells for potential diabetes therapies.
• Compare the pros and cons of islet transplantation versus whole pancreas transplantation for type 1 diabetes.
• Learn about the role of CRISPR gene editing in developing novel treatments for diabetes mellitus.

Beyond Injections: Could Engineered Tissues Hold the Key to Insulin Production?

Exploring the experimental frontiers of transplantation and genetic engineering for treating diabetes mellitus.

You've asked a thought-provoking hypothetical question about whether transplanting or genetically engineering tissues, perhaps even derived from tumors or forming new organ-like structures, could secrete insulin to treat diabetes mellitus. This query touches upon cutting-edge areas of biomedical research aimed at restoring the body's natural insulin production, potentially revolutionizing diabetes management. As of today, Saturday, 2025-04-19, while the direct transplantation of malignant tumors is not a viable therapeutic strategy, related concepts involving cell transplantation and genetic engineering are actively being pursued.

Key Insights

• Islet Transplantation: A current experimental therapy involves transplanting insulin-producing islet cells from donor pancreases to restore natural insulin secretion, though challenges like immune rejection persist.
• Genetic Engineering Frontiers: Researchers are actively engineering various cell types (including stem cells and sometimes utilizing knowledge gained from tumor cell lines in lab settings) and creating lab-grown 'organoids' to produce insulin in a controlled manner.
• Tumor Transplantation Not Viable: Directly transplanting cancerous tumors to produce insulin is not pursued due to significant safety risks (uncontrolled growth, malignancy). However, research sometimes involves genetically modifying cell lines derived from tumors (like insulinomas) under controlled laboratory conditions.

Current Transplant Approaches: Restoring Natural Function

Existing experimental therapies focus on replacing or supplementing the function of the pancreas's insulin-producing cells.

Pancreatic Islet Transplantation

What it entails

One of the most established experimental methods is pancreatic islet transplantation. Islets are tiny clusters of cells within the pancreas containing beta cells, which naturally produce and secrete insulin in response to blood sugar levels. In this procedure, islets are isolated from a deceased donor's pancreas and infused into the recipient, typically into the portal vein of the liver. Once engrafted, these cells can sense glucose levels and release insulin accordingly.

Goals and Outcomes

The primary goal is to restore the body's own regulated insulin secretion, leading to better blood glucose control, reduced risk of severe hypoglycemia (low blood sugar), and potentially eliminating the need for daily insulin injections. Studies have shown that transplanted islets can function for years, significantly improving quality of life and potentially halting the progression of diabetes-related complications.

Current diabetes management often involves insulin delivery via injections, which transplantation aims to replace or supplement.

Hurdles Remain

Despite its promise, islet transplantation faces significant challenges. Firstly, the supply of donor pancreases is limited. Secondly, the recipient's immune system often recognizes the transplanted cells as foreign and attacks them (rejection). To prevent this, patients require lifelong immunosuppressive drugs, which carry their own risks, including increased susceptibility to infections and certain cancers. Lastly, the transplanted islets may gradually lose function over time.

Whole Pancreas Transplantation

A More Invasive Option

Transplanting the entire pancreas is another, albeit less common, option. This procedure can fully restore normal insulin production. However, it involves major surgery and carries significant risks. It is typically reserved for individuals with type 1 diabetes who are also undergoing a kidney transplant or those with severe, life-threatening complications from diabetes that cannot be managed otherwise. Like islet transplantation, it necessitates lifelong immunosuppression.

The Frontier of Genetic Engineering: Building Insulin Factories

Recognizing the limitations of transplantation, researchers are exploring genetic engineering to create customized, sustainable sources of insulin-producing cells.

Engineering Cells for Insulin Production

Modifying Cells to Make Insulin

Scientists are working on genetically modifying various types of cells—such as stem cells or even other mature cell types like liver cells—to produce and secrete insulin. The goal is to insert the human insulin gene along with regulatory elements that allow the cells to release insulin appropriately in response to changing glucose levels.

Ensuring Glucose Responsiveness

A critical aspect is ensuring these engineered cells don't just produce insulin, but release it at the right time and in the right amounts. Uncontrolled insulin release could lead to dangerous hypoglycemia. Therefore, research focuses on creating cells that mimic the sophisticated glucose-sensing and insulin-secreting mechanisms of natural beta cells.

Novel Control Mechanisms

Beyond mimicking natural processes, innovative approaches are being explored. For instance, research has demonstrated engineered human cells that produce insulin when stimulated by a small electric current, potentially allowing for external control. Another advanced area involves designing "synthetic gene circuits" within cells. These circuits act like biological computers, sensing metabolic signals (like glucose or fatty acids) and triggering the production of therapeutic proteins, such as insulin, on demand.

The Role of Tumor-Derived Cells (Research Context)

Your question specifically mentioned tumors. While transplanting a *cancerous* tumor is not a therapeutic strategy due to obvious dangers, some early *research* has utilized cell lines derived from tumors, particularly insulinomas (pancreatic tumors that naturally overproduce insulin). Scientists have genetically engineered these lab-grown cell lines (like K cells mentioned in some studies) to control their insulin production, linking it to glucose levels. This allows researchers to study insulin secretion mechanisms in a controlled environment. It's crucial to differentiate this laboratory use from any notion of transplanting malignant tissue into patients. Historical animal studies also involved transplantable insulin-producing tumors (e.g., in irradiated rats) purely for research purposes.

Creating Insulin-Secreting Organoids

Lab-Grown Mini-Organs

A particularly exciting development is the creation of pancreatic organoids, sometimes called human islet-like organoids (HILOs). These are three-dimensional structures grown in the lab from stem cells (like pluripotent stem cells) or other progenitor cells. They are coaxed to differentiate into various pancreatic cell types, including insulin-producing beta cells, forming structures that resemble natural islets.

Potential Advantages

Organoids offer several potential advantages. They could provide a virtually unlimited supply of insulin-producing tissue, overcoming the donor shortage. Furthermore, because they can be generated from a patient's own cells (after reprogramming them into stem cells), they might be less likely to be rejected by the immune system, potentially reducing or eliminating the need for immunosuppressive drugs. Research is also exploring ways to engineer these organoids to be "invisible" to the immune system.

Enhancing Functionality

To improve the survival and function of organoids after transplantation, scientists are incorporating other cell types, such as endothelial cells (which form blood vessels), into the structure. This helps the organoids integrate better with the host's blood supply, ensuring they receive the nutrients and oxygen needed to function effectively. Studies in animal models have shown promising results, with engineered organoids successfully reversing diabetes.

Research into engineered tissues and organoids represents a move towards more sophisticated, potentially curative therapies.

Visualizing the Landscape: Comparing Approaches

To better understand how these experimental approaches stack up against current treatments and each other, we can visualize some key characteristics. The following chart provides a simplified comparison based on current understanding and future goals.

Comparative Aspects of Treatment Approaches

This radar chart compares conventional insulin injections, current islet transplantation, and the theoretical potential of future engineered cells/organoids across several factors. Higher scores generally indicate more favorable characteristics (e.g., higher Efficacy, lower Invasiveness, lower Immunosuppression need).

Key Concepts in Engineered Insulin Production

The field involves a complex interplay of biological and technological concepts. This mindmap outlines the major themes:

Addressing Safety and Feasibility

While the potential is exciting, significant hurdles must be overcome before these experimental approaches become standard treatments.

Why Not Transplant Tumors Directly?

As mentioned earlier, directly transplanting a naturally occurring insulin-secreting tumor (insulinoma) or any malignant tumor is not a viable therapeutic strategy. The primary reasons include:

• Malignancy Risk: Cancerous cells grow uncontrollably and can spread (metastasize) throughout the body, which is inherently dangerous.
• Uncontrolled Secretion: Insulinomas typically secrete insulin erratically and excessively, leading to severe and unpredictable hypoglycemia (dangerously low blood sugar), which can be life-threatening.
• Pathological Nature: These tumors are disease states that require treatment (usually surgical removal), not conditions to be harnessed for therapy.

The focus is therefore on highly controlled, engineered cells or tissues where insulin production can be precisely regulated and the risk of uncontrolled growth is minimized through careful design and testing.

Hurdles and Future Directions

The path to clinical application for engineered insulin-producing tissues involves overcoming several major obstacles:

• Immune System: Preventing rejection without long-term, broad immunosuppression remains a primary challenge.
• Durability: Ensuring the transplanted cells or tissues survive and function reliably for many years.
• Safety: Rigorously demonstrating that engineered cells will not form tumors or cause other adverse effects.
• Regulation: Achieving precise, physiological control of insulin secretion in response to blood glucose fluctuations.
• Scalability: Developing methods to produce these cells or organoids in the large quantities needed for widespread clinical use.

The future likely lies in combining advances in stem cell biology, gene editing (like CRISPR), tissue engineering, biomaterials (for encapsulation or support), and immunology to create safe, effective, and durable solutions for restoring insulin production in people with diabetes.

Related Technologies and Insights

While researchers work on biological cures, technology also offers ways to manage diabetes by automating insulin delivery.

The "Artificial Pancreas"

Often referred to as automated insulin delivery (AID) systems or closed-loop systems, the "artificial pancreas" is not a biological organ but a technological solution. It typically consists of three components: a continuous glucose monitor (CGM) that tracks blood sugar levels, an insulin pump that delivers insulin, and a control algorithm (often running on a smartphone or integrated into the pump) that automatically adjusts insulin delivery based on the CGM readings. These systems significantly improve glucose control and reduce the burden of diabetes management for many users, mimicking some aspects of natural pancreatic function.

Artificial pancreas systems combine continuous glucose monitoring (CGM) and insulin pumps for automated insulin delivery.

Video Insight: Islet Cell Transplantation Explained

To provide more context on one of the key experimental transplantation methods discussed, the following video offers an overview of islet cell transplantation for type 1 diabetes. It helps illustrate the procedure and its goals as researchers work towards improving diabetes treatment beyond conventional methods.

This video discusses islet cell transplantation, a procedure where insulin-producing cells from a donor pancreas are infused into a patient, usually targeting individuals with difficult-to-control type 1 diabetes. It highlights the potential to restore natural insulin production and improve glucose stability, touching upon the experimental nature and ongoing research in this field, which serves as a stepping stone towards more advanced cell-based therapies like engineered organoids.

Understanding the Basics: Key Terms

Navigating this topic involves some specific terminology. This table provides brief definitions for key concepts:

Frequently Asked Questions (FAQs)

References

• A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion - PMC
• Glucose-dependent insulin release from genetically engineered K cells - PubMed
• Insulin-Producing Organoids: Hope for Treating Type 1 Diabetes - NIH Director's Blog
• Recent advances in designing implantable insulin-secreting heterocellular islet organoids to increase the efficacy of islet transplantation therapy - PubMed
• Pancreas and Islet Transplantation in Type 1 Diabetes Mellitus: Strengths and Weaknesses - PMC
• ‘Gentle’ islet cell transplant cures mice of diabetes without immunosuppression - Stanford Medicine News
• Generation of insulin-secreting organoids: A step toward transplantation therapy for diabetes mellitus - PMC

Recommended

Explore the latest advancements in islet cell encapsulation technology to avoid immunosuppression.

Discover how stem cells are being used to generate functional beta cells for potential diabetes therapies.

Compare the pros and cons of islet transplantation versus whole pancreas transplantation for type 1 diabetes.

Learn about the role of CRISPR gene editing in developing novel treatments for diabetes mellitus.

sciencedirect.com

Designing insulin for diabetes therapy by protein engineering - ...

nlm.nih.gov

How did they make insulin from recombinant DNA? - National Library of ...

pubmed.ncbi.nlm.nih.gov

Glucose-dependent insulin release from genetically engineered ... - PubMed

cell.com

Reversal of diabetes following transplantation of an insulin-secreting ...

my.clevelandclinic.org

Insulinoma: What It Is, Causes, Symptoms & Treatment

sciencedirect.com

Insulin Therapy: The Discovery That Shaped a Century - ScienceDirect

pubmed.ncbi.nlm.nih.gov

[Treatment diabetes by transplantation of insulin secreting cells. Part I] - PubMed

onlinelibrary.wiley.com

Generation of insulin‐secreting organoids: a step toward engineering and transplanting the bioartificial pancreas - Wassmer - 2020 - Transplant International - Wiley Online Library

sciencedirect.com

Islets Transplanted Intraportally into the Liver are Stimulated to ...

tandfonline.com

Insulin secretion and action after pancreas transplantation. A ...

directorsblog.nih.gov

Insulin-Producing Organoids Offer Hope for Treating Type 1 Diabetes – NIH Director's Blog

nhs.uk

Insulin for type 2 diabetes - NHS

nature.com

Synthetic gene circuits: Insulin self-regulation - Nature

sciencedirect.com

Recent advances in the design of implantable insulin secreting ...

newsinhealth.nih.gov

Experimental Therapy Shows Promise for Type 1 Diabetes | NIH News ...

nejm.org

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin ...

pubmed.ncbi.nlm.nih.gov

A Randomized Trial of Intensive Insulin Therapy in Newly ... - PubMed

cancercenter.com

Insulinoma: Symptoms, Diagnosis, Treatment & Prognosis

med.stanford.edu

'Gentle' islet cell transplant cures mice of diabetes with few side effects, Stanford Medicine researchers say

en.wikipedia.org

Insulinoma - Wikipedia

nhsbt.nhs.uk

Who is able to have a pancreas transplant?

uptodate.com

Pancreas and islet transplantation in diabetes mellitus

breakthrought1d.org

100, 100: Genetically Engineered Human Insulin Created

diabetesjournals.org

Clinical Outcomes and Insulin Secretion After Islet Transplantation ...

nejm.org

Insulin Efsitora versus Degludec in Type 2 Diabetes without ...

erc.bioscientifica.com

An update on genetically engineered mouse models of pancreatic ...

pubmed.ncbi.nlm.nih.gov

Recent advances in the design of implantable insulin secreting heterocellular islet organoids - PubMed

ncbi.nlm.nih.gov

Pancreas transplant in type 1 diabetes mellitus: the emerging role of islet cell transplant - PMC

pubmed.ncbi.nlm.nih.gov

Frontiers in transplantation of insulin-secreting tissue for diabetes mellitus - PubMed

nejm.org

The Effect of Intensive Treatment of Diabetes on the Development ...

mayoclinic.org

Diabetes treatment: Using insulin to manage blood sugar - Mayo Clinic

hopkinsmedicine.org

Insulinoma | Johns Hopkins Medicine

medicalnewstoday.com

Type 2 diabetes: Experimental therapy could remove need for insulin

medicalnewstoday.com

Diabetes: Experimental drug may help restore insulin production

aafp.org

Type 2 Diabetes Mellitus: Outpatient Insulin Management | AAFP

pmc.ncbi.nlm.nih.gov

Insulin secretion and insulin-producing tumors - PMC

news.cornell.edu

Islet-transplantation procedure shows promises against T1 diabetes

onlinelibrary.wiley.com

An update of contemporary insulin therapy - Tsai - Wiley Online Library

hopkinsmedicine.org

Experimental Type 1 Diabetes Drug Shelters Pancreas Cells from ...

medlineplus.gov

Insulinoma: MedlinePlus Medical Encyclopedia

pmc.ncbi.nlm.nih.gov

Generation of insulin‐secreting organoids: a step toward ...

stemcellres.biomedcentral.com

Current status of stem cell therapy for type 1 diabetes: a critique ...

nature.com

Real-world effectiveness of early insulin therapy on the incidence ...

pmc.ncbi.nlm.nih.gov

Finally! A human pancreatic β cell line - PMC - PubMed Central (PMC)

nature.com

Experimental insulin implant uses electricity to control genes - Nature

news.stanford.edu

Experimental two-in-one shot could aid diabetics | Stanford Report

sciencedirect.com

Molecular alterations during insulinoma tumorigenesis - ScienceDirect

mayoclinic.org

Pancreas transplant - Mayo Clinic